Key result
In patients with advanced gynecologic and breast malignancies, liposomal doxorubicin, bevacizumab, and temsirolimus yielded a 37.9% clinical benefit rate (CR, PR, or SD ≥6 months).
Why the study?
Does the combination of liposomal doxorubicin, bevacizumab, and temsirolimus show safety and preliminary efficacy in patients with advanced gynecologic and breast malignancies?
Population
74 patients with advanced gynecologic and breast malignancies who received at least one dose of drug on…
Design
Cohort
Authors
Loading...
Supports further testing in PI3K-aberrant tumors; should not yet change practice in advanced gynecologic or breast cancers.
Does the combination of liposomal doxorubicin, bevacizumab, and temsirolimus show safety and preliminary efficacy in patients with advanced gynecologic and breast malignancies?
The combination of liposomal doxorubicin, bevacizumab, and temsirolimus is well tolerated and shows preliminary efficacy, particularly in patients with PI3K pathway aberrations.
Moroney et al. (2011) studied Advanced Gynecologic and Breast Malignancies (n=74). Liposomal doxorubicin, bevacizumab, and temsirolimus (DAT) was evaluated on Clinical benefit (complete response, partial response, or stable disease ≥ 6 months). In patients with advanced gynecologic and breast malignancies, liposomal doxorubicin, bevacizumab, and temsirolimus yielded a 37.9% clinical benefit rate (CR, PR, or SD ≥6 months).
Synapse has enriched one closely related paper. Consider it for comparative context: